Pfizer Pays $330M Upfront for Starna's In Vivo CAR-T Autoimmune Pipeline
PFE sits 20% above its 52-week low of $23.62.
Summary
Pfizer is licensing three early-stage autoimmune programs from Starna Therapeutics, paying $330 million upfront with up to $2.3 billion more tied to development and commercial milestones, plus royalties on sales. The deal gives Pfizer exclusive rights outside Greater China to the three in vivo CAR-T programs, with an option to add that region later, plus options to license compounds from a separate research collaboration and access to Starna's proprietary in vivo CAR-T technology for inflammation, immunology and oncology applications. The three initial programs remain at the pre-investigational new drug application stage; Pfizer leads clinical development outside Greater China and manufactures finished drug products for initial clinical trials at its U.S. facilities. The assets are in vivo CAR-T therapies, an emerging approach Pfizer's inflammation chief Michael Vincent called promising for patients poorly served by current options. The upfront is small against Pfizer's scale, so the near-term financial impact is modest; the real question is whether these early programs survive clinical development. This adds to a busy stretch of pipeline news, following the October tilrekimig Phase 2 win and the Metsera GLP-1 acquisition.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Pfizer's Starna deal gives it exclusive rights outside Greater China to three in vivo CAR-T programs, plus options to license compounds from a separate research collaboration.
- Pfizer leads clinical development outside Greater China; manufactures finished drug products for initial clinical trials at its U.S. facilities
- The three initial programs remain at the pre-investigational new drug application stage
- Pfizer gains access to Starna's proprietary in vivo CAR-T technology for inflammation, immunology and oncology applications
At the time of this announcement, PFE was trading at $28.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $162.3B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.